Who
Barbara Troupin
Director
Company insider
Files Form 4 as: Director, Equillium; Chief Medical Officer, Neurogene; SVP, Chief Medical Officer, Apricus Biosciences.
In numbers
- Trades disclosed
- 15
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 12 Dec 2014
- Last trade
- 28 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 29 May 2026 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 21 May 2025filed 23 May 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 22 May 2024filed 23 May 2024 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 22 May 2023filed 23 May 2023 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 1 Mar 2022filed 8 Mar 2022 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 9 Mar 2018filed 13 Mar 2018 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 8 Mar 2017filed 10 Mar 2017 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 8 Nov 2016filed 10 Nov 2016 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 Mar 2016filed 17 Mar 2016 | Apricus Biosciences | SEC FORM 4 Code A | —43,918 | filing |
| 15 Mar 2016filed 17 Mar 2016 | Apricus Biosciencesoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 29 Jan 2015filed 30 Jan 2015 | Apricus Biosciencesoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Dec 2014filed 15 Dec 2014 | Apricus Biosciencesoption or derivative | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.